What's new
Newsletters "UptoDate" of BASG/AGES MEA are published monthly and contain the latest articles from the last month (link to subscription page).
For the RSS feed with daily notification of updates, use the link: RSS feed to "what's new".
Searched for "active".
Safety warnings
|
messages in brief
|
17/04/2014
Situation Austria: currently only parallel marketed Italian Herceptin and Alimta are affected (as of 18.4.2014). The drug Herceptin is approved throughout Europe for the treatment of early breast cancer, metastatic breast cancer and metastatic…
Safety warnings
|
Medicines
|
17/04/2014
Update from the European Medicines Agency on stolen vials of Herceptin and other affected products
Safety warnings
|
Medicines
|
16/04/2014
The European Medicines Agency received information that vials of Herceptin, a drug used to treat cancer, were adulterated and introduced into the legal distribution chain.
Safety warnings
|
messages in brief
|
16/04/2014
European Medicines Agency warns against counterfeit Herceptin
Replacement
|
Medicines
|
14/04/2014
The marketing authorization holder has informed its wholesalers in a letter dated April 11, 2014, that the contract manufacturer for "Paroxetine-ratiopharm 20 mg Film-Coated Tablets" has received a "Warning letter" from the FDA (US Food and Drug…
Replacement
|
Medicines
|
14/04/2014
The marketing authorization holder informed its wholesalers in a letter dated April 10, 2014, that GlaxoSmithKline (GSK) had received a warning letter from the FDA (US Food and Drug Administration) with concerns about the release of the active…
Recall
|
Medicines
|
20/03/2014
The marketing authorization holder informed its supplied customers in a letter dated 19.03.2014 that underfilling of the15 ml package size had been detected. This is not a case of underfilling during production, but of evaporation of the alcohol due…
Safety warnings
|
messages in brief
|
21/02/2014
European Medicines Agency recommends restriction of use of Protelos/Osseor
Replacement
|
Medicines
|
23/01/2014
The marketing authorization holder informed its supplied customers in a letter dated 23.01.2014 that the batches listed show deviations in dissolution. The release of the active ingredient amitriptyline after four hours is slightly higher than…
Safety warnings
|
messages in brief
|
20/12/2013
The preparation Eldisin 5 mg dry ampoules (active ingredient: vindesine sulfate) has been approved in Austria since March 29, 1984. Vindesine is a cytostatic drug from the group of vinca alkaloids and has proven effective primarily in combination…